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Abstract This study is based on the context that many
patients with advanced oropharyngeal carcinoma are being
treated with primary chemoradiation. The aims of this
study are to identify diVerences in quality of life (QOL)
between patients with advanced oropharyngeal cancer fol-
lowing traditional chemoradiation versus chemotherapy
with intensity-modulated radiation therapy (CIMRT). This
research is designed on a cohort study from an academic
tertiary referral center. Fifty patients were identiWed from
an institutional database of patients who had undergone pri-
mary chemotherapy and radiation (traditional or IMRT) for
advanced oropharyngeal carcinoma. Patients responded via
mail using the University of Washington quality of life
instrument version 4. Statistical analysis of data was per-
formed using Chi-square and Wilcoxon tests. The results
comprise the responses of 17 CRT (57%) and 14 CIMRT
(70%) patients. The patients completed the survey between
9 and 44 months following end of treatment. When
adjusted for tumor stage and time since treatment, CIMRT
patients reported improved appearance (p = 0.05), chewing
(p = 0.02), and mood (p = 0.01). There was a trend toward
signiWcance for improved activity (p = 0.07), recreation
(p = 0.07), and anxiety (p = 0.08). There were no diVer-
ences between the two groups for saliva, taste, shoulder
function, speech, and swallowing. But there was a trend for
signiWcance for improved overall QOL in patients who had
undergone CIMRT (p = 0.06). In conclusion, CIMRT
results in improved QOL for some domains but surprisingly
not for swallowing or saliva. Patients undergoing CIMRT
also report slightly better QOL overall when compared
to patients receiving more traditional forms of radiation
therapy.
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Introduction
The landmark Veterans Administration Laryngeal Cooper-
ative study published in 1991 initiated the era of organ
preservation [1]. Today, many patients are advised to
choose chemoradiation as their primary treatment for
advanced oropharyngeal carcinomas (stages III–IV) [2, 3].
Traditional radiotherapy involves opposed port beams
directed at the tumor. This type of radiation aVects all the
surrounding tissues as well. In oropharyngeal lesions, this
typically results in high doses to the parotids, submandibu-
lar glands, and the mandible (>60 Gy). The resulting long-
term complications of xerostomia and osteoradionecrosis
are well known and negatively impact patients’ quality of
life (QOL). Recent advances in computational power have
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allowed radiation therapy to be directed more speciWcally
to the tumor bed. This conformational therapy is referred to
as intensity-modulated radiotherapy (IMRT). The goal of
using IMRT is to limit the radiation dose to radiosensitive
structures, such as the parotids and the mandible. Within
the literature, studies have demonstrated improved dosime-
try to salivary structures with resultant-improved salivary
Xow [4]. The literature has demonstrated that IMRT proto-
cols provide equivalent control rates and overall survival
when compared to more traditional opposed port therapy
[5]. However, it is unclear how the improved dosimetry
impacts QOL of long-term head and neck cancer survivors.
The other component of the organ preservation protocols
for oropharyngeal carcinoma is chemotherapy. The proto-
cols for this treatment are still being perfected, but the
mainstay of chemotherapy for head and neck carcinomas
involves 5-Xurouracil, a nucleotide analog, and cisplatin—a
DNA chelating agent. Docetaxel is also now being added to
this regimen [6]. The side eVects of these agents can be
severe and include neutropenia, mucositis, renal toxicity,
neuropathy, and hearing loss. Terrell et al. [7] demonstrated
that the addition of chemotherapy to treatment negatively
impacts QOL of patients.
QOL is a subjective perception by the patient that
includes physical, emotional, and social well being. It is
well established that diVerent subsites within the head and
neck have diVerent perceived QOL following treatment;
patients with oropharyngeal carcinoma tend to report worse
QOL than do other head and neck cancer patients and have
poorer functional outcomes [8,  9]. Furthermore, speciWc
aspects of treatment greatly aVect a patient’s QOL. The
need for gastrostomy and tracheostomy tubes, comorbid
medical conditions, and need for a neck dissection all nega-
tively aVect QOL outcomes [7].
A previous study demonstrated no diVerence in QOL
outcomes between patients who had undergone chemoradi-
ation versus surgery and radiation for advanced oropharyn-
geal carcinoma [10]. In the current study a comparison
between QOL outcomes between patients who received
chemotherapy and IMRT (CIMRT) versus standard chemo-
radiation with opposed port therapy (CRT) was undertaken.
The hypothesis of this study is that CIMRT patients experi-
ence improved QOL compared to those undergoing CRT.
Materials and methods
An institutional review board protocol was approved for
this study. Patients were recruited from a tertiary referral
center from a registry of patients who had undergone radia-
tion therapy of all types from 2001 to 2006. Patients had
biopsy-proven squamous cell carcinoma of the oropharynx
(including tonsil, base of tongue, or pharynx). These
tumors were clinically staged as stage II through IV based
on criteria described by the American Joint Committee on
Cancer (AJCC). All patients involved in the study had
undergone either primary concurrent chemoradiation
(CRT) or concurrent chemotherapy with IMRT (Table 1).
Patients were excluded if they required surgical salvage
after CRT/CIMRT or had metastatic disease at the time of
diagnosis.
A total of 50 patients identiWed from institutional dat-
abases met eligibility requirements for the study. All eligi-
ble patients were mailed copies of the University of
Washington Quality of Life Questionnaire, version four
(UW-QOLv4). Patients were also contacted by telephone to
encourage participation. Patients voluntarily Wlled out the
questionnaire at home and mailed their responses to the
Table 1 Chemotherapy and radiation protocol for study participants
NA records not available, 5FU 5 Xuorouracil, carbo carboplatin
a Patient moved from area before Wnishing treatment
ID no. TNM XRT type Total XRT 
dose
Chemo
1 T4N1 Conventional 7,020 Cisplatin/etoposide
2 T3N2b Conventional 7,020 2£ cisplatin/5FU
3 T3N2c Conventional 7,000 2£ cisplatin/5FU
4 T1N1 Conventional 7,200 1£ cisplatin/5FU
5 T2N0 Conventional 7,000 2£ carbo/5FU
6 T3N2 Conventional 7,020 2£ cisplatin/5FU
7 T3N2b Conventional 5,400a 2£ cisplatin/5FU
8 T1N2b Conventional 7,200 2£ cisplatin/5FU
9 T4N1 Conventional 7,380 2£ cisplatin/5FU
10 T2N1 Conventional 7,000 2£ cisplatin/5FU
11 T4N1 Conventional 7,020 2£ cisplatin/5FU
12 T4N3 Conventional 7,020 2£ cisplatin/5FU
13 T4N1 Conventional 7,560 3£ cisplatin
14 T3N3 Conventional NA NA
15 T4N0 Conventional NA NA
16 T4N0 Conventional 7,020 2£ cisplatin/5FU
17 T4N3 IMRT 7,000 2£ cisplatin
18 T2N0 IMRT 7,000 2£ cisplatin
19 T2N2a IMRT 7,000 3£ cisplatin/5FU
20 T1N2b IMRT 7,000 2£ cisplatin/5FU
21 T2N1 IMRT 7,000 2£ cisplatin
22 T2N2 IMRT 6,800 3£ cisplatin
23 T2N0 IMRT 7,000 2£ cisplatin
24 T2N2b IMRT 7,000 4£ cisplatin
25 T4N3 IMRT 7,000 2£ cisplatin
26 T3N2 IMRT 6,800 ERBITUX
27 T1N2b IMRT 7,000 2£ cisplatin
28 T3N2b IMRT 7,000 2£ cisplatin
29 T2N0 IMRT 6,800 None
30 T3N1 IMRT 6,800 2£ cisplatinEur Arch Otorhinolaryngol (2010) 267:1111–1116 1113
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study organizers. Questionnaires were identiWed by a non-
descript number, and data were entered into a conWdential
database.
The UW-QOLv4 instrument is scored on a scale of 0–100
for the Wrst and third segments. The Wrst section consists of
12 domains pertaining to the degree of QOL in the categories
of pain, appearance, activity, recreation, swallowing, chewing,
speech, shoulder function, taste, saliva, mood, and anxi-
ety. A score of 0 indicates very poor or no functional
capacity with regard to that domain while a score of 100
indicates no disability in that domain. The second segment of
the questionnaire asks patients to choose three of the above
domains that have been the most important to them in the
past 7 days. In the Wnal part of the instrument, patients are
given three general questions comparing their (1) current
health-related quality of life (HR-QOL) to 1 month before
developing cancer, (2) HR-QOL during the past 7 days, and
(3) overall QOL during the past 7 days. The Wnal segment is
scored with 0 indicating very poor QOL and 100 indicating
outstanding QOL, with a range of scores between.
Statistical analysis of the responses was conducted using
the Wilcoxon rank sum test and the Chi-square test. Results
were adjusted to control for time from treatment to ques-
tionnaire and for tumor stage.
Results
Twenty-nine questionnaires were returned (58% return rate),
with 16/30 patients in the CRT cohort and 13/20 in the
CIMRT cohort. All patients were male. Eleven of 16 patients
in the CRT cohort and 9 of 14 patients in the CIMRT group
had stage IV tumors. Each group had one patient who was
staged with T2N0 cancer. There was no statistically signiW-
cant diVerence in the tumor stages between the two groups.
All patients received chemotherapy concomitantly with their
radiation. No patient received induction chemotherapy. One
patient in the CIMRT cohort received cetuximab rather than
5-Xuorouracil or cisplatin. Table 1 shows the various radia-
tion doses and chemotherapy regimens for the responding
patients. The average time between the completion of treat-
ment and questionnaire for the CIMRT group was 13 months
(range 4–22 months) while that for the CRT group was 25
months (range 4–53 months).
Patients who received CIMRT reported statistically sig-
niWcantly better QOL with regard to appearance (p = 0.05),
chewing (p = 0.02), and mood (p = 0.01). There was a trend
toward signiWcance in favor of CIMRT with regard to anxi-
ety (p = 0.08), recreation (p = 0.07), and activity (p = 0.07).
No statistically signiWcant diVerence was reported between
the two cohorts with respect to saliva (p = 0.34), pain
(p = 0.47), swallowing (p = 0.29), speech (p = 0.50), shoul-
der (p = 0.24), and taste (p = 0.32).
With regard to overall QOL and HR-QOL, there was no
diVerence between the two groups (p = 0.31 and 0.09,
respectively). However, when asked about QOL compared
to 1 month before the development of cancer, CIMRT
patients reported improved QOL (p =0 . 0 6 ) .
Discussion
Primary chemotherapy with radiation is a popular treatment
option for patients with advanced oropharyngeal carci-
noma. Recent advances have allowed for conformal radia-
tion treatment strategies in order to minimize complications
in radiosensitive structures. QOL in long-term survivors is
an important outcome measure and is currently an active
area of research. In this study, QOL outcomes were com-
pared in a cohort study between traditional opposed port
radiotherapy and IMRT; both groups received concomitant
chemotherapy. Overall QOL was not diVerent in the
CIMRT patients; however, several domains did demon-
strate improved QOL as measured by the UW-QOLv4.
Appearance, chewing, and mood were better for CIMRT
patients. No diVerence was detected for all other domains,
including saliva, taste, and swallowing.
SpeciWc evaluation of the global and HR-QOL in
patients treated for oropharyngeal carcinoma with IMRT is
limited. The majority of studies available evaluate xerosto-
mia and xerostomia-related QOL [11, 12]. Of the studies
that evaluate global QOL, it has been demonstrated that
IMRT patients experience improved QOL [13, 14].
Yao et al. [13] recently published the only study focused
on oropharyngeal cancer survivors speciWcally. They evalu-
ated 56 patients with the Head and Neck Cancer Inventory
which measures HR-QOL and questions about their diet.
They found that eating and dysphagia scores were signiW-
cantly improved in the IMRT group of patients. Other
domains demonstrated improved QOL scores for IMRT
patients but did not reach statistical signiWcance. Further-
more, 1 year after treatment the IMRT patients’ scores con-
tinued to improve while the CRT patients’ scores had
reached a plateau [13]. In the current study, a diVerent head
and neck speciWc instrument was used, speciWcally the
UW-QOLv4; thus it is somewhat diYcult to compare the
data. However, it is apparent there were diVerences
between the Wndings of the Iowa group and our cohort. In
the present study, only 3 of 12 domains demonstrated sig-
niWcance although several domains approached signiW-
cance. SpeciWcally, patients did not report improved saliva
or swallowing in our study while Yao et al. [13] did report
improvement for these domains.
Other studies in the literature have looked primarily at
either xerostomia-related QOL or dysphagia-related QOL.
Levendag et al. [15] studied the dosimetry to the constrictor1114 Eur Arch Otorhinolaryngol (2010) 267:1111–1116
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muscles in oropharyngeal carcinoma patients and deter-
mined that higher doses delivered to these muscles resulted
in higher rates of severe dysphagia and gastrostomy depen-
dence. Their study is somewhat diYcult to interpret
because not all patients received chemotherapy, which may
lead to increased scarring in the pharyngeal musculature. In
our study, patients received relatively uniform chemother-
apy regimens and similar dosimetry to tumor. The patients
in our cohorts did not report improved swallowing or
saliva, but CIMRT patients did report better chewing. The
noted improvement in chewing may be explained by the
sparing of the intrinsic musculature of the tongue and other
oral structures with IMRT. The ability to manipulate the
bolus within the oral cavity is an integral part of the oral
phase of chewing. Improved tongue mobility due to less
radiation induced Wbrosis potentially accounts for this
result.
The results for saliva are somewhat surprising based on
the radiation protocol in eVect at our institution. All
patients with oropharyngeal primary tumors who undergo
IMRT receive 70 Gy to the gross tumor. Sites within the
oropharynx or neck with likely microscopic disease receive
63 Gy and sites with potential or remote disease receive
56 Gy. The parotid glands are carefully identiWed and
mapped so that 50% of each gland received only 20 Gy.
The rest of the gland receives doses from 56 to 70 Gy (see
Fig. 1). With approximately half of the gland spared from
high dose radiation, recovery of salivary function is
expected within several months after the completion of
treatment. Conversely, patients treated with conventional
(opposed port) radiation do not have sparing of the parotid
glands. For treatment of the oropharynx, the parotids
receive 70 Gy to the entire gland on each side. Minimal sal-
ivary function is expected to return in these patients. Given
the diVerences between the radiation protocols, the lack of
diVerence regarding salivary QOL is surprising. Perhaps
those undergoing IMRT have decreased perception of sali-
vary  Xow when compared to pre-therapy Xow rates and
thus report decreased salivary QOL.
Patients receiving CIMRT did report signiWcantly better
mood and appearance than their CRT counterparts. The
cause of this diVerence is unclear. Perhaps there is less
“woody induration” in IMRT patients, which results in a
more supple appearance to the neck contour and hence an
improved perception of appearance. The results with regard
to mood were unexpected and cannot be explained by a
diVerence either in Wnal XRT dose or in chemotherapy reg-
imens, as these were similar between the groups. QOL is,
by deWnition, a subjective evaluation of the patient’s per-
ception. These results are inherently biased and dependent
on the patient’s expectations of their treatment and its out-
comes. Perhaps, the CIMRT patients reported better mood
because they expected to feel better after treatment.
Other diVerences in the perceived QOL of these patients
may be elucidated with a diVerent QOL instrument. There
are a number of head and neck speciWc questionnaires
available which have been validated in the literature includ-
ing the HR-QOL, EORTC-C30 with the EORTC-H&N35,
and UW-QOL. A recent review by Tschiesner et al. [16]
compared these instruments using the international classiW-
cation of function, disability, and health (ICF) schema.
Using this schema, the content of the instruments can be
more easily compared as the instrument content was corre-
lated with speciWc ICF concepts. The EORTC question-
naires cover a broader range of ICF categories when
compared to the UW-QOL. The EORTC instrument
includes questions regarding memory and attention func-
tions; sexual functions; respiratory functions; a variety of
activities of daily living such as toileting and dressing; and
smell. This instrument is used widely in Europe but less
commonly in the United States. However, both instruments
have approximately 70% of their content that can be corre-
lated to an ICF category; the EORTC instrument covers 43
categories while the UW-QOL covers 23 categories [16].
Two of the major beneWts of the UW-QOL, and the reason
it was chosen for this study, are its broad range of questions
and the relative ease of completion. In order to encourage
participation in the veteran population from which this
cohort was drawn, an instrument which could be completed
Fig. 1 Radiation planning diagram for T4 carcinoma of the right ton-
sil. The primary tumor volume receives 70 Gy (marked T and shaded
in red). The radiation plan is designed to spare 50% of each parotid
gland (blue-shaded area identiWed by the arrowhead). The dose distri-
bution lines show rapid falloV in the radiation dose between the tumor
and the majority of the parotid gland. A small amount of the gland
receives high dose radiation where the tumor approaches the glandEur Arch Otorhinolaryngol (2010) 267:1111–1116 1115
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quickly but covered a broad range of topics was required.
The UW-QOL can be completed in a quarter of the time
needed to complete the EORTC instruments.
The diVerences between the two radiation groups may be
helpful when deciding which radiation modality to use for
speciWc patients. Those patients with comorbid conditions
report having signiWcantly worse QOL prior to beginning
therapy than those without these conditions [17]. In these
patients, all other factors being equal, CIMRT may be a
better option to try to minimize the negative impact of ther-
apy on their already diminished QOL.
Other treatment options for advanced oropharyngeal car-
cinoma include surgery with adjuvant radiation (or chemo-
radiation). QOL outcomes between surgery and opposed
port chemoradiation have been previously described [10].
Surgical therapy is associated with late toxicity, including
scarring, Wbrosis, laryngeal, and esophageal stenoses, all of
which also aVect QOL for head and neck cancer patients.
As both appearance and chewing can be signiWcantly
impacted by surgery, it is possible that patients who
undergo primary CIMRT may have improved QOL com-
pared with patients who undergo surgery and radiation.
Although there were no diVerences noted between the two
chemoradiation groups in the aforementioned study, the
impact of CIMRT on QOL when compared to surgery and
radiation is yet to be explored. Another treatment option
that is available is induction chemotherapy followed by
radiation. While none of the patients in this study received
induction chemotherapy, it is known that chemotherapy, in
general, negatively impacts on QOL [7]. How the timing of
chemotherapy, induction, or concomitant, impacts QOL has
not been explored. It seems likely that although early toxic-
ity of therapy may be diminished in those patients undergo-
ing induction chemotherapy, the long-term eVects on QOL
would be similar to those receiving concomitant chemora-
diation.
This current study is limited in several ways. One limi-
tation to this study was that our sample size was small,
and there may not have been suYcient power to Wnd sig-
niWcant diVerences between the two groups. A larger
number of patients may demonstrate subtle diVerences
between the groups and may result in statistically signiW-
cant diVerences for anxiety, recreation, and activity. An
ideal study would be a prospective longitudinal one
involving a larger number of patients, and in future such
studies are planned. However, we believe that this current
study is a valuable pilot study which yields important
information about what oropharyngeal cancer patients
should expect from CRT and CIMRT, especially when
discussing the beneWts of a given treatment. It is impor-
tant not to overstate the beneWts of that treatment and
ensure that patients have realistic expectations for their
post treatment QOL.
Conclusion
Patients who receive chemotherapy and IMRT do have
improvement in certain domains of QOL, speciWcally
appearance, mood, and chewing. However, with regard to
overall QOL, CIMRT and CRT patients have similar per-
ceptions of QOL. Surprisingly, in our study CIMRT patients
did not report better saliva or swallowing when compared to
CRT patients. Although studies in the literature demonstrate
improved salivary Xow rates with parotid sparing radiation
regimens, this does not appear to have improved the
patients’ perceptions of dry mouth following treatment. This
information is important to understand when counseling
patients regarding the expected treatment outcomes.
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